CYTO — Cytophage Technologies Balance Sheet
0.000.00%
Last trade - 00:00- CA$2.83m
- CA$4.60m
Annual balance sheet for Cytophage Technologies, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|
| Period Length: | — | — | — |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS |
| Standards: | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final |
| Cash | |||
| Cash and Short Term Investments | 4.84 | 2.25 | 0.032 |
| Net Total Accounts Receivable | |||
| Net Total Receivables | 0.095 | 0.456 | 0.345 |
| Prepaid Expenses | |||
| Total Other Current Assets | |||
| Total Current Assets | 4.96 | 2.75 | 2.95 |
| Gross Property, Plant And Equipment | |||
| Accumulated Depreciation | |||
| Net Property, Plant And Equipment | 0.872 | 0.935 | 2.49 |
| Total Assets | 5.83 | 3.69 | 5.44 |
| Accounts Payable | |||
| Payable / Accrued | |||
| Accrued Expenses | |||
| Notes Payable / Short Term Debt | |||
| Current Portion of Long Term Debt / Capital Leases | |||
| Total Other Current Liabilities | |||
| Total Current Liabilities | 0.173 | 0.238 | 3.64 |
| Capital Lease Obligations | |||
| Total Long Term Debt | |||
| Total Debt | |||
| Total Liabilities | 0.281 | 0.238 | 5.07 |
| Common Stock | |||
| Retained Earnings (Accumulated Deficit) | |||
| Total Equity | 5.55 | 3.45 | 0.373 |
| Total Liabilities & Shareholders' Equity | 5.83 | 3.69 | 5.44 |
| Total Common Shares Outstanding |